Plain-English translation of ·
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether lower doses of a medication called post-transplantation (PTCy) work just as well as standard doses when combined with two other medications to prevent rejection after stem cell transplant. Researchers want to find the lowest effective dose that keeps people safe while preventing a serious complication called graft-versus-host disease, where the new immune cells attack the body.
The standard dose of this medication was chosen many years ago partly by guesswork, but newer research suggests that lower doses might work just as well—or even better—with fewer side effects. This trial will determine the safest and most effective dose for people receiving stem cell transplants.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive a stem cell transplant followed by the medication being tested on specific days after your transplant. You will likely have frequent clinic visits and blood tests in the months after transplant to monitor how well the treatment works and check for side effects. The trial is divided into two phases: the first phase determines the best dose, and the second phase tests whether that dose truly works well for preventing rejection.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States